CHEMBIO DIAGNOSTICS INC (CEMI)
US1635722093 - Common Stock
Taking everything into account, CEMI scores 1 out of 10 in our fundamental rating. CEMI was compared to 192 industry peers in the Health Care Equipment & Supplies industry. CEMI may be in some trouble as it scores bad on both profitability and health. CEMI is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year CEMI has reported negative net income.
In the past year CEMI has reported a negative cash flow from operations.
CEMI had negative earnings in each of the past 5 years.
CEMI had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
CEMI has negative profitability rations, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
CEMI has a Gross Margin of 22.10%. This is in the lower half of the industry: CEMI underperforms 78.20% of its industry peers.
In the last couple of years the Gross Margin of CEMI has declined.
The Profit Margin and Operating Margin are not available for CEMI so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 22.1% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-14.23%
GM growth 5Y-13.7%
2. Health
2.1 Basic Checks
CEMI does not have a ROIC to compare to the WACC, probably because it is not profitable.
CEMI has more shares outstanding than it did 1 year ago.
CEMI has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, CEMI has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -3.34, we must say that CEMI is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -3.34, CEMI is not doing good in the industry: 65.40% of the companies in the same industry are doing better.
A Debt/Equity ratio of 0.00 indicates that CEMI is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.00, CEMI is in the better half of the industry, outperforming 65.88% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -3.34 |
ROIC/WACCN/A
WACC9.13%
2.3 Liquidity
A Current Ratio of 1.23 indicates that CEMI should not have too much problems paying its short term obligations.
CEMI has a Current ratio of 1.23. This is amonst the worse of the industry: CEMI underperforms 82.94% of its industry peers.
CEMI has a Quick Ratio of 1.04. This is a normal value and indicates that CEMI is financially healthy and should not expect problems in meeting its short term obligations.
CEMI's Quick ratio of 1.04 is on the low side compared to the rest of the industry. CEMI is outperformed by 78.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.23 | ||
| Quick Ratio | 1.04 |
3. Growth
3.1 Past
CEMI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 45.07%, which is quite impressive.
The Revenue has been growing slightly by 3.57% in the past year.
Measured over the past years, CEMI shows a quite strong growth in Revenue. The Revenue has been growing by 15.57% on average per year.
EPS 1Y (TTM)45.07%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q94.95%
Revenue 1Y (TTM)3.57%
Revenue growth 3Y12.85%
Revenue growth 5Y15.57%
Revenue growth Q2Q-49.72%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
CEMI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
CEMI does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CHEMBIO DIAGNOSTICS INC
NASDAQ:CEMI (4/27/2023, 7:20:06 PM)
After market: 0.4311 -0.02 (-5.25%)0.455
+0 (+0.22%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap16.71M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 22.1% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.79
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.23 | ||
| Quick Ratio | 1.04 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)45.07%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next YN/A
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)3.57%
Revenue growth 3Y12.85%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y